• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测肝门部胆管癌根治性切除术后无复发生存的预后模型的开发与验证:一项多中心研究

Development and Validation of a Prognostic Model to Predict Recurrence-Free Survival After Curative Resection for Perihilar Cholangiocarcinoma: A Multicenter Study.

作者信息

Liu Zhi-Peng, Chen Wei-Yue, Wang Zi-Ran, Liu Xing-Chao, Fan Hai-Ning, Xu Lei, Pan Yu, Zhong Shi-Yun, Xie Dan, Bai Jie, Jiang Yan, Zhang Yan-Qi, Dai Hai-Su, Chen Zhi-Yu

机构信息

Department of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.

Department of Clinical Research Institute, Lishui Hospital of Zhejiang University, Lishui, China.

出版信息

Front Oncol. 2022 Apr 21;12:849053. doi: 10.3389/fonc.2022.849053. eCollection 2022.

DOI:10.3389/fonc.2022.849053
PMID:35530316
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9071302/
Abstract

BACKGROUND

Recurrence is the main cause of death in perihilar cholangiocarcinoma (pCCA) patients after surgery. Identifying patients with a high risk of recurrence is important for decision-making regarding neoadjuvant therapy to improve long-term outcomes.

AIM

The objective of this study was to develop and validate a prognostic model to predict recurrence-free survival (RFS) after curative resection of pCCA.

METHODS

Patients following curative resection for pCCA from January 2008 to January 2016 were identified from a multicenter database. Using random assignment, 70% of patients were assigned to the training cohort, and the remaining 30% were assigned to the validation cohort. Independent predictors of RFS after curative resection for pCCA were identified and used to construct a prognostic model. The predictive performance of the model was assessed using calibration curves and the C-index.

RESULTS

A total of 341 patients were included. The median overall survival (OS) was 22 months, and the median RFS was 14 months. Independent predictors associated with RFS included lymph node involvement, macrovascular invasion, microvascular invasion, maximum tumor size, tumor differentiation, and carbohydrate antigen 19-9. The model incorporating these factors to predict 1-year RFS demonstrated better calibration and better performance than the 8th American Joint Committee on Cancer (AJCC) staging system in both the training and validation cohorts (C-indexes: 0.723 0.641; 0.743 0.607).

CONCLUSIONS

The prognostic model could identify patients at high risk of recurrence for pCCA to inform patients and surgeons, help guide decision-making for postoperative adjuvant therapy, and improve survival.

摘要

背景

复发是肝门部胆管癌(pCCA)患者术后死亡的主要原因。识别具有高复发风险的患者对于决定新辅助治疗以改善长期预后非常重要。

目的

本研究的目的是开发并验证一种预测模型,以预测pCCA根治性切除术后的无复发生存期(RFS)。

方法

从多中心数据库中确定2008年1月至2016年1月期间接受pCCA根治性切除的患者。通过随机分配,70%的患者被分配到训练队列,其余30%被分配到验证队列。确定pCCA根治性切除术后RFS的独立预测因素,并用于构建预后模型。使用校准曲线和C指数评估该模型的预测性能。

结果

共纳入341例患者。中位总生存期(OS)为22个月,中位RFS为14个月。与RFS相关的独立预测因素包括淋巴结受累、大血管侵犯、微血管侵犯、最大肿瘤大小、肿瘤分化程度和糖类抗原19-9。在训练队列和验证队列中,纳入这些因素预测1年RFS的模型均显示出比美国癌症联合委员会(AJCC)第8版分期系统更好的校准和性能(C指数:训练队列0.723对0.641;验证队列0.743对0.607)。

结论

该预后模型可以识别pCCA高复发风险患者,为患者和外科医生提供信息,帮助指导术后辅助治疗决策,并提高生存率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f4/9071302/77dffdd1cdb8/fonc-12-849053-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f4/9071302/176ef66a3b44/fonc-12-849053-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f4/9071302/aa6c00e3e133/fonc-12-849053-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f4/9071302/e0103e7ec7e1/fonc-12-849053-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f4/9071302/77dffdd1cdb8/fonc-12-849053-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f4/9071302/176ef66a3b44/fonc-12-849053-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f4/9071302/aa6c00e3e133/fonc-12-849053-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f4/9071302/e0103e7ec7e1/fonc-12-849053-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f4/9071302/77dffdd1cdb8/fonc-12-849053-g004.jpg

相似文献

1
Development and Validation of a Prognostic Model to Predict Recurrence-Free Survival After Curative Resection for Perihilar Cholangiocarcinoma: A Multicenter Study.预测肝门部胆管癌根治性切除术后无复发生存的预后模型的开发与验证:一项多中心研究
Front Oncol. 2022 Apr 21;12:849053. doi: 10.3389/fonc.2022.849053. eCollection 2022.
2
Development of a model based on the age-adjusted Charlson comorbidity index to predict survival for resected perihilar cholangiocarcinoma.基于年龄调整后的Charlson合并症指数建立模型以预测肝门部胆管癌切除术后生存率
World J Gastrointest Oncol. 2023 Jun 15;15(6):1036-1050. doi: 10.4251/wjgo.v15.i6.1036.
3
Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.开发和评估一种临床计算器,用于估计接受化疗、放疗和手术治疗的局部晚期直肠癌患者的复发和生存可能性。
JAMA Netw Open. 2021 Nov 1;4(11):e2133457. doi: 10.1001/jamanetworkopen.2021.33457.
4
Impact of perioperative blood transfusion on long-term survival in patients with different stages of perihilar cholangiocarcinoma treated with curative resection: .围手术期输血对接受根治性切除的不同分期肝门部胆管癌患者长期生存的影响:
Front Oncol. 2022 Oct 31;12:1059581. doi: 10.3389/fonc.2022.1059581. eCollection 2022.
5
Impact of Body Mass Index on Tumor Recurrence in Patients Undergoing Liver Resection for Perihilar Cholangiocarcinoma (pCCA).体重指数对肝门部胆管癌(pCCA)肝切除患者肿瘤复发的影响
Cancers (Basel). 2021 Sep 24;13(19):4772. doi: 10.3390/cancers13194772.
6
Machine learning model to predict early recurrence in patients with perihilar cholangiocarcinoma planned treatment with curative resection: a multicenter study.预测计划进行根治性切除的肝门部胆管癌患者早期复发的机器学习模型:一项多中心研究
J Gastrointest Surg. 2024 Dec;28(12):2039-2047. doi: 10.1016/j.gassur.2024.09.027. Epub 2024 Oct 3.
7
A novel prognostic nomogram for patients with surgically resected perihilar cholangiocarcinoma: a SEER-based study.一种用于手术切除的肝门周围胆管癌患者的新型预后列线图:一项基于监测、流行病学和最终结果(SEER)数据库的研究
Ann Transl Med. 2021 Jan;9(1):54. doi: 10.21037/atm-20-3130.
8
Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram.肝门周围胆管癌切除术后的生存情况——一种预后列线图的开发与外部验证
Ann Oncol. 2015 Sep;26(9):1930-1935. doi: 10.1093/annonc/mdv279. Epub 2015 Jun 30.
9
Radiographic features predictive of recurrence and survival after surgical resection of perihilar cholangiocarcinoma.肝门周围胆管癌手术切除后预测复发和生存的影像学特征。
Heliyon. 2024 Mar 29;10(7):e28805. doi: 10.1016/j.heliyon.2024.e28805. eCollection 2024 Apr 15.
10
Development and external validation of a prognosis model to predict outcomes after curative resection of early-stage intrahepatic cholangiocarcinoma.预测早期肝内胆管癌根治性切除术后预后的模型的开发与外部验证
Front Surg. 2023 Mar 8;10:1102871. doi: 10.3389/fsurg.2023.1102871. eCollection 2023.

引用本文的文献

1
Anatomical hepatectomy for achieving textbook outcome for perihilar cholangiocarcinoma treated with curative-intent resection: A multicenter study.旨在通过根治性切除实现肝门部胆管癌教科书式治疗效果的解剖性肝切除术:一项多中心研究。
ILIVER. 2022 Nov 13;1(4):245-251. doi: 10.1016/j.iliver.2022.10.004. eCollection 2022 Dec.
2
Short- and long-term outcomes of laparoscopic versus open resection of perihilar cholangiocarcinoma: a propensity score-based analysis.腹腔镜与开腹手术切除肝门部胆管癌的短期和长期预后:一项基于倾向评分的分析
Hepatobiliary Surg Nutr. 2025 Apr 1;14(2):207-221. doi: 10.21037/hbsn-23-680. Epub 2024 Aug 12.
3

本文引用的文献

1
Postoperative morbidity adversely impacts oncological prognosis after curative resection for hilar cholangiocarcinoma.术后并发症对可切除性肝门部胆管癌根治术后的肿瘤预后有不良影响。
World J Gastroenterol. 2022 Mar 7;28(9):948-960. doi: 10.3748/wjg.v28.i9.948.
2
Evaluation of Four Lymph Node Classifications for the Prediction of Survival in Hilar Cholangiocarcinoma.四种淋巴结分类方法对肝门部胆管癌生存预测的评估。
J Gastrointest Surg. 2022 May;26(5):1030-1040. doi: 10.1007/s11605-021-05211-x. Epub 2022 Jan 1.
3
Cholangiocarcinoma.胆管癌。
Clinical features and prediction of long-term survival after surgery for perihilar cholangiocarcinoma.
肝门部胆管癌手术治疗的临床特征及长期生存预测。
PLoS One. 2024 Jul 1;19(7):e0304838. doi: 10.1371/journal.pone.0304838. eCollection 2024.
4
Residual biliary intraepithelial neoplasia without malignant transformation at resection margin for perihilar cholangiocarcinoma does not require expanded resection: a dual center retrospective study.肝门周围胆管癌切缘残留无恶性转化的胆管上皮内瘤变不需要扩大切除:一项双中心回顾性研究。
World J Surg Oncol. 2024 Jun 21;22(1):161. doi: 10.1186/s12957-024-03395-5.
5
AI-based digital histopathology for perihilar cholangiocarcinoma: A step, not a jump.基于人工智能的肝门周围胆管癌数字组织病理学:循序渐进,而非一蹴而就。
J Pathol Inform. 2023 Nov 5;15:100345. doi: 10.1016/j.jpi.2023.100345. eCollection 2024 Dec.
6
Assessment of the prognostic value of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in perihilar cholangiocarcinoma patients following curative resection: .评估根治性切除术后肝门周围胆管癌患者中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值的预后价值:
Front Oncol. 2023 Jan 4;12:1104810. doi: 10.3389/fonc.2022.1104810. eCollection 2022.
7
Impact of perioperative blood transfusion on long-term survival in patients with different stages of perihilar cholangiocarcinoma treated with curative resection: .围手术期输血对接受根治性切除的不同分期肝门部胆管癌患者长期生存的影响:
Front Oncol. 2022 Oct 31;12:1059581. doi: 10.3389/fonc.2022.1059581. eCollection 2022.
Nat Rev Dis Primers. 2021 Sep 9;7(1):65. doi: 10.1038/s41572-021-00300-2.
4
Multi-Institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma.多机构开发和外部验证用于预测肝癌根治性切除术后肝外复发的列线图。
Ann Surg Oncol. 2021 Nov;28(12):7624-7633. doi: 10.1245/s10434-021-10142-7. Epub 2021 May 21.
5
Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients.基于增强 CT 影像组学构建预测晚期 HCC 患者抗 PD-1 抗体治疗疗效的列线图模型的建立与验证
Front Immunol. 2021 Jan 8;11:613946. doi: 10.3389/fimmu.2020.613946. eCollection 2020.
6
Development and external validation of a nomogram for predicting the effect of tumor size on survival of patients with perihilar cholangiocarcinoma.建立并外部验证一个列线图模型,用于预测肿瘤大小对肝门部胆管癌患者生存的影响。
BMC Cancer. 2020 Oct 30;20(1):1044. doi: 10.1186/s12885-020-07501-0.
7
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.ivosidenib 治疗 IDH1 突变、化疗耐药性胆管癌(ClarIDHy):一项多中心、随机、双盲、安慰剂对照、3 期研究。
Lancet Oncol. 2020 Jun;21(6):796-807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13.
8
Surgical Resection and Prognostic Analysis of 142 Cases of Hilar Cholangiocarcinoma.142例肝门部胆管癌的手术切除及预后分析
Indian J Surg. 2018 Aug;80(4):309-317. doi: 10.1007/s12262-016-1581-z. Epub 2017 Jan 7.
9
Nomograms predict survival outcome of Klatskin tumors patients.列线图可预测肝门部胆管癌患者的生存结局。
PeerJ. 2020 Feb 18;8:e8570. doi: 10.7717/peerj.8570. eCollection 2020.
10
Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: A systematic review and meta-analysis.胆管癌手术的系统辅助化疗:系统评价和荟萃分析。
Eur J Surg Oncol. 2020 Apr;46(4 Pt A):684-693. doi: 10.1016/j.ejso.2019.11.499. Epub 2019 Nov 15.